Charissa W Kam (Charissa Kam)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Pseudomonas Aeruginosa

Replacement Therapy

Top Venues

Pediatric pulmonology

ERJ open research

This page only lists publications with an associated author ORCID identifier.

Publications

Martina Gentzsch, Brooke Baker, Deborah M Cholon, Charissa W Kam, Cameron J McKinzie, Katherine A Despotes, Susan E Boyles, Nancy L Quinney, Charles R Esther, Carla M P Ribeiro
Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303K CFTR mutation. ERJ open research 10 (1) (2024)
Cameron J McKinzie, Charissa W Kam, Morgan C Jones, Laura B Gifford, Ceila E Loughlin, Terry L Noah, Vivek K Shenoy, Elisabeth P Dellon
Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis. Pediatric pulmonology 59 (6) (2024)
Martina Gentzsch, Brooke Baker, Deborah M Cholon, Charissa W Kam, Cameron J McKinzie, Katherine A Despotes, Susan E Boyles, Nancy L Quinney, Charles R Esther, Carla M P Ribeiro
Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303K CFTR mutation. ERJ open research 10 (1) (2024)
Cameron J McKinzie, Charissa W Kam, Morgan C Jones, Laura B Gifford, Ceila E Loughlin, Terry L Noah, Vivek K Shenoy, Elisabeth P Dellon
Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis. Pediatric pulmonology 59 (6) (2024)
Richard De Vuyst, Charissa W Kam, Cameron J McKinzie, Charles R Esther
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor. Pediatric pulmonology (2024)
Martina Gentzsch, Brooke Baker, Deborah M Cholon, Charissa W Kam, Cameron J McKinzie, Katherine A Despotes, Susan E Boyles, Nancy L Quinney, Charles R Esther, Carla M P Ribeiro
Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303K CFTR mutation. ERJ open research 10 (1) (2024)
Cameron J McKinzie, Stephanie R Duehlmeyer, Charissa W Kam, Julie Safirstein
Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy. Pediatric pulmonology (2024)
Richard De Vuyst, Charissa W Kam, Cameron J McKinzie, Charles R Esther
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor. Pediatric pulmonology 59 (7) (2024)
Cameron J McKinzie, Charissa W Kam, Morgan C Jones, Laura B Gifford, Ceila E Loughlin, Terry L Noah, Vivek K Shenoy, Elisabeth P Dellon
Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis. Pediatric pulmonology (2024)
Richard De Vuyst, Charissa W Kam, Cameron J McKinzie, Charles R Esther
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor. Pediatric pulmonology 59 (7) (2024)
Richard C De Vuyst, Erin Bennard, Charissa W Kam, Cameron J McKinzie, Charles R Esther
Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatric pulmonology (2023)
Richard C De Vuyst, Erin Bennard, Charissa W Kam, Cameron J McKinzie, Charles R Esther
Elexacaftor/tezacaftor/ivacaftor Treatment Reduces Airway Inflammation in Cystic Fibrosis. Pediatric pulmonology (2023)
Cameron J McKinzie, Charissa W Kam, Jeffrey T Zobell, David C Young
Effective pharmacy provider handoff communication for transition of patient care in CF. Pediatric pulmonology (2023)
Cameron J McKinzie, Charissa W Kam, Rachel Parry, Marcus Darby, Casey R Tak
Pharmacist-administered audiology screening for pediatric cystic fibrosis patients exposed to high-dose aminoglycosides: A pilot study. Pediatric pulmonology 57 (7) (2022)
Charissa W Kam, Fadel E Ruiz
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children. Pediatric pulmonology 56 (3) (2020)